We are excited to share that Jennifer Che, President and Managing Director of Eagle IP, will be attending the Life Sciences Patents Network (LSPN) North America Spring conference, held from April 29–30, 2026, at the Hyatt Regency Boston.

As a premier gathering for the global biopharma and medtech communities, LSPN Boston provides a vital platform for IP leaders to discuss the strategies and legal frameworks driving innovation in the life sciences. With her extensive background as  a medicinal chemist, US Patent Attorney, and Managing Director of a team of Chinese patent attorneys, Jennifer is uniquely positioned to engage with industry peers on the complex IP challenges, especially with respect to Asia, facing modern biotech companies.

If you are attending LSPN Boston and would like to discuss global IP strategy or specific developments in the Asian markets, Jennifer would welcome the opportunity to connect. Please contact us to schedule a meeting during the conference.

我們過去活動

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

2026年6月16日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

2026年6月5日

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2026年6月2日

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

2026年5月8日

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

2026年5月8日

Eagle IP to Attend INTA 2026 Annual Meeting in London

2026年5月2日

Recommended Insights

Breaking: China Released New Implementation Measures for the New Patent Linkage System

2021年7月14日
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]
閱讀更多 >

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]
閱讀更多 >

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
閱讀更多 >

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

2021年12月6日
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]
閱讀更多 >
Top crossarrow-right